Vista Pharmaceuticals (BOM:524711) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Vista Pharmaceuticals EBITDA Margin % Related Terms
Vista Pharmaceuticals EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Vista Pharmaceuticals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524711 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vista Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vista Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vista Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Vista Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vista Pharmaceuticals (BOM:524711) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vista Pharmaceuticals and its competitors. According to the industry distribution chart, Vista Pharmaceuticals ranks #906 out of 961 companies in the Drug Manufacturers industry, placing it in the top 94.3%.
Is Vista Pharmaceuticals' EBITDA Margin % too high?
Vista Pharmaceuticals' current EBITDA Margin % is 0.00%. Based on the distribution chart, Vista Pharmaceuticals ranks #906 out of 961 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vista Pharmaceuticals has a GF Score™ of 47/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vista Pharmaceuticals' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vista Pharmaceuticals ranks #906 out of 961 companies for EBITDA Margin %. This places Vista Pharmaceuticals in the lower half of its industry. The industry median EBITDA Margin % is 12.49. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vista Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vista Pharmaceuticals's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vista Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vista Pharmaceuticals (BOM:524711) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹6.05, compared to a current price of ₹7.28 — trading 20.3% above its estimated fair value. The current EBITDA Margin % is 0.00%. Vista Pharmaceuticals' overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Vista Pharmaceuticals (BOM:524711), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vista Pharmaceuticals (BOM:524711) Overvalued in 2026?
Based on GuruFocus' analysis, Vista Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹7.28 is trading 20.3% above its estimated GF Value™ of ₹6.05.
GuruFocus considers Vista Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for BOM:524711:
EBITDA Margin %: 0.00%
GF Value™: ₹6.05 vs. price of ₹7.28 (20.3% above fair value)
No single metric tells the full story. See the BOM:524711 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vista Pharmaceuticals Ltd is an Indian company engaged in a single operating segment, which is the manufacturing of Pharmaceutical products. The company offers over-the-counter and prescription generic drug products such as tablets, capsules, and liquids covering various therapeutic categories. Some of the drugs in tablet dosage forms are Sulfamethoxazole and Trimethoprim, Bismuth Subgallate, Pyrantel Pamoate, Aspirin, Ibuprofen, Ranitidine HCl, and others. Nifedipine, Piroxicam, and Indomethacin are the drugs offered by the company in a capsule dosage form. The company generates all of its operating revenue from sales within its domestic market.
47GF Score
Get the complete analysis for BOM:524711
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524711 has been successfully added to your 
